Peter Hoskin, MD, of Mount Vernon Cancer Centre, discusses study findings on single-dose radiotherapy compared with multifraction radiotherapy in patients with metastatic spinal canal compression. (Abstract LBA10004)
Daniel A. Goldstein, MD, of Emory University and Rabin Medical Center, discusses his study findings that show nearly $1 billion in savings when patients receive personal weight-based doses instead of a predetermined fixed dose for treatment of PD-L1-positive non–small cell lung cancer. (Abstract 9013)
Olivier Tredan, MD, PhD, of the Centre Léon Bérard, discusses results from ProfilER, a study that explored the use of cancer cell genomic alterations to guide treatment in patients with advanced refractory cancer. (Abstract LBA100)
Gary Rodin, MD, of the University of Toronto, discusses study findings on a systematic approach to alleviating distress and managing predictable challenges. (Abstract LBA10001)
David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, outlines abstracts focusing on chemotherapy in locally advanced rectal cancer and immune-related toxicity, response to anti–PD-L1 blockade, and epacadostat plus pembrolizumab in lung cancer.
Greta Stifel recounts her story about a misdiagnosed tumor and urges physicians to raise awareness of neuroendocrine disease.
